Industry Supported Sessions

​​​​

​Hall 1

Tuesday, 12 May 2015

15.00 - 16.30

GSK

Dilemma of providing vaccine advice to parents beyond national 
recommendations: the case for varicella and meningococcal v​​​accines​​

17.00 - 18.30

ASTRAZENECA

The future of infectious disease prevention: evolving paradigms in influenza vaccination​ 


Wednesday, 13 May 2015

08.45 - 10.15

  SANOFI PASTEUR MSD

Hexavalent, Varicella and HPV vaccinations: Advances& Challenges

10.45 - 12.15

PFIZER

Where we are: Prevention of CNS and mucosal infections

13.00 - 14.30

GSK

Pertus​sis caught in the crossfire​

15.00 - 16.30

NOVARTIS VACCINES

BEXSERO® in Practice: International Experience to Date

16.50 - 18.20

GSK

Is it time for vaccination to 'go viral'? How to maintain and increase vaccine acceptance and coverage for all age groups in the digital era

​​

Tuesday, 12 May, 2015

gsk.jpg  

Dilemma of providing vaccine advice to parents beyond national recommendations: the case for varicella and meningococcal vaccines

15.00-16.30

Chair: Marco A. Sáfadi, Brazil

Participants:   Marc Van Ranst, Belgium

                        Michael Horn, Germany

                        Paolo Bonanni, Italy

Time Presenter
15:00- 15:15Making vaccine recommendations – societal versus individual decision makingM. Sáfadi
15.15 - 16.10

Roundtable discussion:

"Counselling parents on the benefits and risks of varicella and meningococcal immunization"

  • What are the common concerns and misconceptions?
  • Are varicella and meningococcal vaccines safe & efficacious?
  • Is it reasonable to vaccinate against varicella and meningococcal disease?  

M. Sáfadi

M. Van Ranst

M. Horn

P. Bonanni

16.10 - 16.25Q&AAll
16.25 -16.30Concluding remarksM. Sáfadi

 

*************

astra.jpg 

The future of infectious disease prevention: evolving paradigms in influenza vaccination

17:00–18:30

​TimingSession titleSpeaker(s)
17:00–17:05Welcome and introductionsMarkus Rose (Chair; Germany)
17:05–17:20 Learning lessons from the past to inform future approaches to vaccination

Mary Slack

(UK)

17:20–17:35Know your enemy – flu: highly adaptable, often costly, sometimes deadlyMarc Van Ranst (Belgium)
17:35–17:55Prevention of flu: taking a look at the science, the evidence and implementation of vaccination programmes in the real world

Markus Rose

(Chair; Germany) and Sharon White (UK)

17:55–18:25

 

The shifting sands of influenza vaccination: key considerations for decision makers – a panel discussion and audience Q&APanel discussion will be moderated by Markus Rose (Chair; Germany)
18:25–18:30Conclusions and summaryMarkus Rose (Chair; Germany)

 

Wednesday, 13 May, 2015

sanofi.jpg

Hexavalent, Varicella and HPV vaccinations: Advances& Challenges

08:45-10:15​

TimingSession titleSpeaker
08:45-08:50IntroductionUlrich Heininger (Chair; Switzerland)
08:50-09:10Fully liquid hexavalent vaccine: update with EU clinical studiesProf. Vassiliki Papaevangelou (Greece)
09:10-09-30Hexavalent vaccination in clinical practice: towards better quality managementChristoph Bornhöft (Germany)
09:30-09:50Reaching universal varicella vaccination with a new MMRV combined vaccine 

Paolo Bonanni

(Italy)

09:50-10:10Universal HPV vaccination: the Austrian experience

Elmar Joura

(Austria)

10:10-10:15Summary / ConclusionUlrich Heininger (Chair; Switzerland)

*************


Where we are: Prevention of CNS and mucosal infections

10:45-12:15

Chair: Professor Markus Knuf (Germany)

Co-Chair: Professor Heinz-Josef Schmitt (France)

 

 

10:45                     Welcome and Introduction

Professor Markus Knuf (Germany), Professor Heinz-Josef Schmitt (France)

 

10:50                     Impact of PCV13 worldwide

Professor Markus Knuf (Germany)

 

11:00                     Pneumococcal conjugate vaccines: linking immunogenicity to public health impact

Professor Ron Dagan (Israel)​

 

11:40                     TBE in children: a call for prevention

Doctor Mikael Sundin (Sweden)

 

12:00                     Discussion and Q&A / Summary

​*************

gsk.jpg 

Pertussis caught in the crossfire

13:00-14:30

Chair: Prof. Dr Ron Dagan (Israel)

Participants:   Prof. Dr Carl-Heinz Wirsing von König (Germany)

                        Dr Alberto Tozzi (Italy)

                        Dr Gayatri Amirthalingam (United Kingdom)

                        Dr Linda Hanssens (GSK Vaccines, Belgium)

13:00-13:05Welcome and introduction
13:05-14:20

Round table discussion including the following topics:

  • What lessons have we learned from recent pertussis outbreaks?
  • Do current vaccination schedules work?
  • How can we protect the vulnerable baby?
  • Do we need pertussis boosters throughout life?
14:20-14:30Concluding remarks and Q&A


*************

Novartis 

BEXSERO® in Practice: International Experience to Date

15:00-16:30

Topics

15:00-15:10

Welcome and Introduction

Rino Rappuoli and Markus Knuf, Program Co-Chairs

 

15:10-15:25

Recommendation of BEXSERO in the United Kingdom
Linda Glennie

 

15:25-15:40

Investigational Use of BEXSERO in the United States: University Experience

Robin Izzo

 

15:40-15:55

Use of BEXSERO in Germany: A Pediatrician's Perspective
Michael Horn

 

15:55–16:20

Use of BEXSERO in Canada: A Regional Intervention in Québec

Philippe De Wals

 

16:20–16:30

Q&A and Closing Remarks

Rino Rappuoli and Markus Knuf, Program Co-Chairs

 

*************

gsk.jpg 

Is it time for vaccination to 'go viral'? How to maintain and increase vaccine acceptance and coverage for all age groups in the digital era

16:50-18:20

 

16.50–16.55

Introduction:

What people want to know about vaccines

 

 

Dr Marla Shapiro (Canada)

 

16.55​–18.00

Round table discussion:

Is it time for vaccination to 'go viral'?:  How to maintain and increase vaccine acceptance and coverage for all age groups in the digital era

The role of the healthcare professional

The policy maker's perspective 

The vaccine industry's role 


The anthropologist's perspective

The journalist's role


 

 

 

 

 


Dr Roy K. Philip (Ireland)

Prof. Pierre Van Damme (Belgium) 

Dr Steffen Glismann (Belgium, GSK Vaccines)

Dr Pauline Paterson (United Kingdom)

Dr Marla Shapiro (Canada)


 

 

18.00– 18.15Q&A 
18.15– 18.20Concluding remarks Dr Marla Shapiro (Canada)

 

 

Keep Me Updated